French biotechnology company Valneva SE (EPA:VLA) has reported positive Phase III results for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001, Reuters news agency reported on Monday.
According to the company, its latest trial conducted on 4,012 participants aged 18 and older across 26 trial sites in Britain, showed the vaccine prompted a stronger immune response and fewer side-effects than AstraZeneca's (LON:AZN) shot.
Reportedly, Valneva is among a handful of vaccine developers testing their vaccines against one already approved by a regulator, rather than giving volunteers a placebo as shots become more available.
Valneva's Chief Executive, Thomas Lingelbach, was quoted as saying: "These results confirm the advantages often associated with inactivated whole virus vaccines," adding that the company believed it would make an important contribution to the fight against COVID-19.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval